portfolio

Active Portfolio

Exits

Gemphire Therapeutics

Developer of novel drugs to treat the large unmet medical need of patients with high cardiovascular and pancreatitis risk who are unable to reach goals with current therapies –initially targeting rare orphan indications. IPO in 2016.

Ocuphire

Biopharmaceutical company developing drugs to treat ophthalmic disorders. Preservative-free Nyxol® Eye Drops, is for multiple front-of-the-eye indications, including night vision disturbances, reversal of pharmacologically-induced mydriasis, and presbyopia.